US EditionPublished • loading... • Updated
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals raised $6 million through a Nasdaq-priced direct offering to fund LYMPHIR's commercial launch and support development of its product pipeline.
- Yesterday, Citius Pharmaceuticals Inc. closed a registered direct offering priced at-the-market under Nasdaq rules, selling securities at $1.51 per share from Cranford, N.J.
- Under a shelf registration filed December 27, 2024, and declared effective January 27, 2025, the securities were offered under Nasdaq rules and conducted via a prospectus.
- The financing raised approximately $6.0 million in gross proceeds, before placement agent fees and offering expenses, and included common warrants exercisable immediately at $1.40 that expire in five years.
- Citius Pharma intends to use net proceeds to support LYMPHIR's commercial launch, including milestone, regulatory, and development payments, while engaging the U.S. Food and Drug Administration on next steps.
- The press release includes "forward-looking statements" disclaiming any obligation to update, cautioning that risks include funding needs and Nasdaq compliance, Citius Pharmaceuticals Inc. said.
Insights by Ground AI
51 Articles
51 Articles
The Berkshire Eagle+49 Reposted by 49 other sources
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered…
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (2025-10-21)
-Citius Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreement for the purchase of an aggregate of 3,973,510 shares of its common stock and accompanying common warrants to purchase up to an aggregate of...
·United States
Read Full ArticleCoverage Details
Total News Sources51
Leaning Left3Leaning Right8Center14Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
12%
C 56%
R 32%
Factuality
To view factuality data please Upgrade to Premium
